Q&A With Danny McBryan From Boehringer Ingelheim: New Data Shows COPD Medication Could Help Asthma Patients Better Manage Symptoms

Video

Asthma is a common problem in the medical community and even while there are many treatment options on the market, controlling symptoms of the condition continues to be an issue for patients and doctors alike.

Asthma is a common problem in the medical community and even while there are many treatment options on the market controlling symptoms of the condition continues to be an issue for patients and doctors alike.

Danny McBryan, MD, who serves as vice president Clinical Development and Medical Affairs, Respiratory, for Boehringer Ingelheim Pharmaceuticals reported on data showing that SPIRIVA, a medication already approved for patients with COPD could have benefits for patients needing to better control their asthma symptoms as well. The data was presented at the annual CHEST conference held in Montreal.

Related Videos
Video 10 - "Future Treatment Landscape for COPD"
Video 9 - "Emerging Treatment Approaches in COPD"
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
A panel of 4 experts on asthma
A panel of 4 experts on asthma
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
© 2024 MJH Life Sciences

All rights reserved.